Floatz logo

Gm-Csf

Malignant Melanoma

Ultimovacs ASAPhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
81/ 100

Competitive context

450 Active assets in the Malignant Melanoma cohort.

Asset / SponsorPhaseRating
Sargramostim
Mayo Clinic
Phase 3BBB
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
DACARBAZINE
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 3BB
Alpha-Interferon
Hoffmann-La Roche
Phase 2/3BB

View all 50 →

Same molecule, other indications

Gm-Csf is also rated in:

acute lymphoblastic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →